CAS No.:2589-47-1

TOXICITY DATA with REFERENCE：

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
guinea pig	LDLo	intravenous	330ug/kg (0.33mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 22, Pg. 2085, 1972.
man	TDLo	oral	1400ug/kg (1.4mg/kg)	behavioral: "hallucinations, distorted perceptions"	British Medical Journal. Vol. 2, Pg. 675, 1977.
man	TDLo	oral	22857ug/kg/20 (22.857mg/kg)	liver: "jaundice, cholestatic" blood: eosinophilia skin and appendages (skin): "dermatitis, other: after systemic exposure"	Postgraduate Medical Journal. Vol. 56, Pg. 738, 1980.
mouse	LD50	intraperitoneal	21265ug/kg (21.265mg/kg)		United States Patent Document. Vol. #4552877,
mouse	LD50	intravenous	1700ug/kg (1.7mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 22, Pg. 2085, 1972.
mouse	LD50	oral	33714ug/kg (33.714mg/kg)		United States Patent Document. Vol. #4552877,
rat	LD50	intravenous	3400ug/kg (3.4mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 22, Pg. 2085, 1972.
rat	LD50	oral	54mg/kg (54mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 22, Pg. 2085, 1972.
women	LDLo	oral	22mg/kg (22mg/kg)		Archives of Toxicology. Vol. 37, Pg. 135, 1977.

Consensus Reports：

 

SAFETY PROFILE：

Poison by ingestion and intravenous routes. An experimental teratogen. Human systemic effects by ingestion: hallucinations and distorted perceptions. Experimental reproductive effects. An antiarrhythmic agent. When heated to decomposition it emits toxic fumes of NO_x.

Standards and Recommendations：

 

Analytical Methods：